In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity

American Journal of Physiology - Renal Physiology

Volumn 276, Issue 3 45-3, 1999, Pages

  Johnson, David W ^a   Saunders, Heather J ^a   Field, Michael J ^a   Pollock, Carol A ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

3 Hydroxy 3 methylglutaryl CoA reductase; Insulin like growth factor binding proteins; Insulin like growth factor I; Platelet derived growth factor; Transforming growth factor

Indexed keywords

CYCLOSPORIN; PLATELET DERIVED GROWTH FACTOR; SIMVASTATIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CREATININE CLEARANCE; DRUG EFFECT; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE;

EID: 0032895195     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.1999.276.3.f467     Document Type: Article

References (50)

1. Arnadottir, M., L. O. Eriksson, H. Thysell, and J. D. Karkas. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron 65: 410-413, 1993.
2. Bing, R. F., A. M. Haegerty, H. Thurston, and J. D. Swales. Ion transport in hypertension: are changes in the cell membrane responsible? Clin. Sci. (Colch.) 71: 225-230, 1986.
3. Bohle, A., G. A. Muller, M. Wehrmann, S. Mackensen-Haen, and J. C. Xiao. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int. 49: S2-S9, 1996.
4. Casey, P. J. Biochemistry of protein prenylation. J. Lipid Res. 33: 1731-1740, 1992.
5. Chan, P. C., J. D. Robinson, W. C. Yeung, I. K. Cheng, H. W. Yeung, and M. T. Tsang. Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol. Dial. Transplant. 7: 93-99, 1992.
6. Davidson, M. H., E. A. Stein, C. A. Dujovne, D. B. Hunninghake, S. R. Weiss, R. H. Knopp, D. R. Illingworth, Y. B. Mitchel, M. R. Melino, R. V. Zupkis, M. R. Dobrinska, R. D. Amin, and J. A. Tobert. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am. J. Cardiol. 79: 38-42, 1997.
7. DeGroen, P. C. Cyclosporine, low-density lipoprotein and cholesterol. Mayo Clin. Proc. 63: 1012-1021, 1988.
8. Feld, S., and R. Hirschberg. Growth hormone, the insulin-like growth factor system and the kidney. Endocr. Rev. 17: 423-480, 1996.
9. Germershausen, J. I., V. M. Hunt, R. G. Bostedor, P. J. Bailey, J. D. Karkas, and A. W. Alberts. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 158: 667-675, 1989.
10. Gile, R. D., B. D. Cowley, Jr., V. H. Gattone II, M. P. O'Donnell, S. K. Swan, and J. J. Grantham. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am. J. Kidney Dis. 26: 501-507, 1995.
11. Gonzalo, A., J. Pascual, F. Mampaso, and J. Ortuno. Remission of nephrotic syndrome on lovastatin treatment. Nephron 66: 233-234, 1994.
12. Grandaliano, G., P. Biswas, G. G. Choudhury, and H. E. Abboud. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int. 44: 503-508, 1993.
13. Grellier, P., M. Sabbah, B. Fouqueray, K. Woodruff, D. Yee, H. E. Abboud, and S. L. Abboud. Characterisation of insulin-like growth factor binding proteins and regulation of IGFBP3 in human mesangial cells. Kidney Int. 49: 1071-1078, 1996.
14. Guarda, E., P. R. Myers, C. G. Brilla, S. C. Tyagi, and K. T. Weber. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc. Res. 27: 1004-1008, 1993.
15. Harris, K. P., M. L. Purkerson, J. Yates, and S. Klahr. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am. J. Kidney Dis. 15: 16-23, 1990.
16. Hostetter, T. H. Progression of renal disease and renal hypertrophy. Annu. Rev. Physiol. 57: 263-278, 1995.
17. Johnson, D. W., B. K. Brew, P. Poronnik, D. I. Cook, M. J. Field, and C. A. Pollock. Transport characteristics of human proximal tubule cells in primary culture. Nephrologie 3: 183-194, 1997.
18. Johnson, D. W., B. K. Brew, P. Poronnik, D. I. Cook, A. Z. Gyory, M. J. Field, and C. A. Pollock. Insulin-like growth factor-1 stimulates apical sodium-hydrogen exchange in human proximal tubule cells. Am. J. Physiol. 272 (Renal Physiol. 41): F484-F490, 1997.
19. Johnson, D. W., H. J. Saunders, B. K. Brew, A. Ganesan, R. C. Baxter, P. Poronnik, D. I. Cook, A. Z. Gyory, M. J. Field, and C. A. Pollock. Human renal fibroblasts modulate proximal tubule cell growth and transport via insulin-like growth factor-I. Kidney Int. 52: 1486-1496, 1997.
20. Johnson, D. W., H. J. Saunders, F. J. Johnson, S. O. Huq, M. J. Field, and C. A. Pollock. Fibrogenic effects of cyclosporin A on the human tubulointerstitium in vitro: roles of insulin-like growth factor-I, platelet-derived growth factor and transforming growth factor-β1 (Abstract). J. Am. Soc. Nephrol. 8: 603A, 1997.
21. Johnson, D. W., H. J. Saunders, P. Poronnik, D. I. Cook, M. J. Field, and C. A. Pollock. Paracrine "cross-talk" between human proximal tubule cells and cortical fibroblasts regulates tubulointerstitial function via insulin-like growth factor-I, platelet-derived growth factor and transforming growth factor-β1 (Abstract). J. Am. Soc. Nephrol. 8: 518A, 1997.
22. Jones, J. I., and D. R. Clemmons. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16: 3-34, 1995.
23. Keane, W. F. Lipids and progressive renal failure. Wien Klin. Wochenschr. 108: 420-424, 1996.
24. Klahr, S., G. Schreiner, and I. Ichikawa. The progression of renal disease. N. Engl. J. Med. 318: 1657-1666, 1988.
25. Lam, K. S., I. K. Cheng, E. D. Janus, and R. W. Pang. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38: 604-609, 1995.
26. Lee, S. K., S. Y. Yin, D. C. Han, S. D. Hwang, and H. B. Lee. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol. Dial. Transplant. 8: 1338-1343, 1993.
27. Lensmeyer, G. L., D. A. Wiebe, I. H. Carlson, and R. Subramanian. Concentrations of cyclosporin A and its metabolites in human tissues postmortem. J. Anal. Toxicol. 15: 110-115, 1991.
28. Martinez-Gonzalez, J., M. Vinals, F. Vidal, V. Llorente Cortes, and L. Badimon. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 135: 213-223, 1997.
29. Minuto, F., A. Barreca, P. Del Monte, and G. Giordano. Paracrine actions of IGF binding proteins. Acta Endocrinol. 24, Suppl. 2: 63-69, 1991.
30. Mitchell, D. B., K. S. Sandone, and D. Acosta. Evaluation of cytotoxicity in cultured cells by enzyme leakage. J. Tiss. Cult. Meth. 6: 113-116, 1981.
31. + antiport activity in diabetic nephropathy. Kidney Int. 41: 872-876, 1992.
32. + exchanger isoforms. Am. J. Physiol. 268 (Cell Physiol. 37): C283-C296, 1995.
33. O'Donnell, M. P., B. L. Kasiske, S. A. Katz, P. G. Schmitz, and W. F. Keane. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20: 651-658, 1992.
34. O'Donnell, M. P., B. L. Kasiske, Y. Kim, D. Atluru, and W. F. Keane. Lovastatin inhibits proliferation of rat mesangial cells. J. Clin. Invest. 91: 83-87, 1993.
35. O'Donnell, M. P., B. L. Kasiske, Y. Kim, P. G. Schmitz, and W. F. Keane. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am. J. Kidney Dis. 22: 83-89, 1993.
36. Olbricht, C. J. Cholesterol in progressive renal disease (Abstract). Nephrologie 3: S39, 1997.
37. Ong, A. C. M., T. P. Jowett, J. E. Scoble, J. A. O'Shea, Z. Varghese, and J. F. Moorhead. Effect of cyclosporin A on endothelin synthesis by cultured human renal cortical epithelial cells. Nephrol. Dial. Transplant. 8: 748-753, 1993.
38. Quesney Huneeus, V., M. H. Wiley, and M. D. Siperstein. Essential role for mevalonate synthesis in DNA replication. Proc. Natl. Acad. Sci. USA 76: 5056-5060, 1979.
39. Rabelink, A. J., T. J. Hene, D. W. Erkelens, J. A. Joles, and H. A. Koomans. Partial remission of nephrotic syndrome in patient on long-term simvastatin. Lancet 335: 1045-1046, 1990.
40. Rosano, T. G., B. M. Freed, M. A. Pell, and N. Lempert. Cyclosporine metabolites in human blood and renal tissue. Transplant. Proc. 18: 35-40, 1986.
41. Sasaki, T., H. Kurata, K. Nomura, K. Utsunomiya, and Y. Ikeda. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn. J. Med. Sci. Biol. 29: 156-163, 1990.
42. Scanferla, F., P. P. Toffoletto, D. Roncali, and G. Bazzato. Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects (Abstract). Am. J. Hypertens. 4: 868, 1991.
43. Sharma, K., Y. Jin, J. Guo, and F. N. Ziyadeh. Neutralisation of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.
44. Sokol, P. P., L. C. Capodagli, M. Dixon, P. D. Holohan, C. R. Ross, R. Coulson, and D. B. Jones. Cyclosporin A and vehicle toxicity in primary cultures of rabbit renal proximal tubule cells. Am. J. Physiol. 259 (Cell Physiol. 28): C897-C903, 1990.
45. Strutz, F., and G. A. Muller. On the progression of chronic renal disease. Nephron 69: 371-379, 1995.
46. Vanderplasschen, A., E. Hanon, C. Benarafa, R. Greimers, A. Op De Beeck, M. Loncar, and P. P. Pastoret. Madin Darby bovine kidney cell synchronization by lovastatin: application to bovine herpesvirus-1 gene expression. Vet. Res. 25: 555-567, 1994.
47. Vincent, T. S., E. Wulfert, and E. Merler. Inhibition of growth factor signaling pathways by lovastatin. Biochem. Biophys. Res. Commun. 180: 1284-1289, 1991.
48. ras activated, AP-1-dependent pathway. Kidney Int. 52: 1016-1027, 1997.
49. Weder, A. B., C. Serr, B. A. Torretti, D. R. Bassett, and A. J. Zweifler. Effects of lovastatin treatment on red blood cell and platelet cation transport. Hypertension 17: 203-209, 1991.
50. Wolf, G., P. D. Killen, and E. G. Neilson. Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J. Am. Soc. Nephrol. 1: 918-922, 1990.